SOX1 Functions as a Tumor Suppressor by Repressing HES1 in Lung Cancer.
HES1
SOX1
lung cancer
tumor suppressor
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
08 Apr 2023
08 Apr 2023
Historique:
received:
10
03
2023
revised:
25
03
2023
accepted:
31
03
2023
medline:
16
5
2023
pubmed:
16
5
2023
entrez:
16
5
2023
Statut:
epublish
Résumé
The development of lung cancer is a complex process that involves many genetic and epigenetic changes. Sex-determining region Y (SRY)-box (SOX) genes encode a family of proteins that are involved in the regulation of embryonic development and cell fate determination. SOX1 is hypermethylated in human cancers. However, the role of SOX1 in the development of lung cancer is unclear. We used quantitative methylation-specific polymerase chain reaction (MSP), quantitative reverse transcription polymerase chain reaction (RT-PCR) analysis, and web tools to confirm the frequent epigenetic silencing of SOX1 in lung cancer. Stable overexpression of SOX1 repressed cell proliferation, anchorage-independent growth, and invasion in vitro as well as cancer growth and metastasis in a xenograft mouse model. Knockdown of SOX1 by the withdrawal of doxycycline partly restored the malignant phenotype of inducible SOX1-expressing NSCLC cells. Next, we discovered the potential downstream pathways of SOX1 using RNA-seq analysis and identified HES1 as a direct target of SOX1 using chromatin immunoprecipitation (ChIP)-PCR. Furthermore, we performed phenotypic rescue experiments to prove that overexpression of HES1-FLAG in SOX1-expressing H1299 cells partly reversed the tumor-suppressive effect. Taken together, these data demonstrated that SOX1 acts as a tumor suppressor by directly inhibiting HES1 during the development of NSCLC.
Identifiants
pubmed: 37190139
pii: cancers15082207
doi: 10.3390/cancers15082207
pmc: PMC10136456
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Nat Commun. 2015 Oct 15;6:8640
pubmed: 26468775
Nucleic Acids Res. 2022 Jul 5;50(W1):W216-W221
pubmed: 35325185
Mol Cancer Res. 2008 Sep;6(9):1421-30
pubmed: 18819930
Int J Mol Sci. 2020 Jul 19;21(14):
pubmed: 32707737
Oncogene. 2016 Apr 28;35(17):2266-78
pubmed: 26257059
Cancer Sci. 2023 Apr;114(4):1635-1650
pubmed: 36411521
Development. 2002 Sep;129(18):4193-203
pubmed: 12183372
Mol Cancer. 2014 Nov 26;13:257
pubmed: 25427424
J Thorac Oncol. 2021 Apr;16(4):653-664
pubmed: 33333328
Sci Rep. 2015 May 21;5:10338
pubmed: 25996086
Oncogene. 2009 May 28;28(21):2163-72
pubmed: 19377513
Nat Med. 2021 Aug;27(8):1345-1356
pubmed: 34385702
J Cancer. 2018 Feb 11;9(4):757-766
pubmed: 29556333
Epigenetics Chromatin. 2019 Dec 5;12(1):71
pubmed: 31805986
Ann Oncol. 2020 Aug;31(8):1056-1064
pubmed: 32418886
J Natl Cancer Inst. 2014 Jan;106(1):djt356
pubmed: 24309006
Genes Dev. 2004 May 1;18(9):1072-87
pubmed: 15132997
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Cancer Biol Ther. 2015;16(3):353-9
pubmed: 25781910
Int J Cancer. 2009 Jan 15;124(2):387-93
pubmed: 18942711
Br J Cancer. 2008 Jan 29;98(2):466-73
pubmed: 18087279
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Sci Rep. 2014 Feb 04;4:3963
pubmed: 24492635
Dev Biol. 2004 May 15;269(2):580-94
pubmed: 15110721
Mol Cancer. 2010 Oct 07;9:267
pubmed: 20929579
Dev Cell. 2002 Aug;3(2):167-70
pubmed: 12194848
Gynecol Oncol. 2013 Oct;131(1):174-81
pubmed: 23927962
Br J Cancer. 2008 Feb 26;98(4):824-31
pubmed: 18268498
Mol Cell Biol. 2007 Nov;27(22):7802-15
pubmed: 17875931
Tumour Biol. 2015 Jun;36(6):4603-10
pubmed: 25613070
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Neoplasia. 2017 Aug;19(8):649-658
pubmed: 28732212
J Cancer Res Ther. 2022 Oct-Dec;18(6):1692-1696
pubmed: 36412431
Cancer Treat Rev. 2018 Jan;62:50-60
pubmed: 29169144
Genes Chromosomes Cancer. 2018 May;57(5):268-277
pubmed: 29363224
Epigenetics. 2010 Nov-Dec;5(8):743-9
pubmed: 20716954
Hepatology. 2012 Dec;56(6):2277-87
pubmed: 22767186
Nature. 1990 Jul 19;346(6281):245-50
pubmed: 2374589
Oncotarget. 2015 Jun 20;6(17):15022-34
pubmed: 25909283
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Semin Cancer Biol. 2020 Dec;67(Pt 1):122-153
pubmed: 30914279
Lancet Oncol. 2019 Jul;20(7):924-937
pubmed: 31122901
Trends Cell Biol. 2015 Nov;25(11):675-686
pubmed: 26437589
Int J Mol Sci. 2019 Nov 25;20(23):
pubmed: 31775307
Cancer Res. 2012 Mar 1;72(5):1301-15
pubmed: 22246670
Exp Ther Med. 2021 Sep;22(3):958
pubmed: 34335900
Cancer Lett. 2016 Jun 28;376(1):10-21
pubmed: 26975630
Int J Cancer. 2008 Jul 1;123(1):161-7
pubmed: 18398837
Biochem Biophys Res Commun. 2017 Jan 1;482(1):15-21
pubmed: 27836540
J Clin Oncol. 2019 Oct 1;37(28):2518-2527
pubmed: 31154919
J Pathol. 2009 Oct;219(2):222-31
pubmed: 19644956
J Neurosci Res. 2009 Nov 15;87(15):3277-87
pubmed: 19437544
Pharmacogenomics J. 2014 Dec;14(6):509-22
pubmed: 24980784